All You Need to Know About Using CBD During Pregnancy
Pregnancy is the most remarkable experience in a woman’s life but it can also be the most uncomfortable one, due to the numerous unpleasant symptoms accompanied by it. These symptoms are both physical and psychological, ranging from nausea, migraine, morning sickness, anxiety and even depression. These days, mothers tend to use natural remedies to ease […]
Pregnancy is the most remarkable experience in a woman’s life but it can also be the most uncomfortable one, due to the numerous unpleasant symptoms accompanied by it. These symptoms are both physical and psychological, ranging from nausea, migraine, morning sickness, anxiety and even depression. These days, mothers tend to use natural remedies to ease these conditions instead of using conventional chemical approaches which have their own negative side effects.
One of the natural remedies, which has recently gained popularity, is cannabidiol, a relatively new variety of cannabis that can potentially reduce pain, anxiety, depression and improve general health. For all these benefits, cannabidiol or CBD has been become a favorite choice for pregnant women to deal pregnancy-related health conditions. But the big concern here is that how CBD may affect the development of the baby. Therefore, CBD oil and pregnancy research are hot topics that bring along a lot of controversies. If you are considering using CBD for any condition related to pregnancy, be sure to do your homework before purchasing any products online and always consult with your physician.
Can You Switch to CBD Oil for Treating Pregnancy-Related Conditions?
Around 50% of pregnant women use pharmaceuticals or over-the-counter drugs such as antidepressants, cold medicine, anti-nausea and sleeping pills. These medications were proven to be unsafe in cases for the fetus and may lead to birth defects. That is the main reason why pregnant women are turning to CBD as a replacement. But on the other side, there are people who are against the use of CBD during pregnancy and believe it is too risky. They argue that its benefits have not even been studied extensively and since the FDA does not regulate CBD products, the level of THC which has the psychoactive effect known as high, may vary a lot in each product. However, there are lots of CBD users who have reported using it as a safe alternative for pain, anxiety and nausea during pregnancy without any complications.
The American College of Obstetricians and Gynecologists has recommended to stop marijuana use in pregnant women and lactating mothers. The reason behind this is that some studies have indications of adverse effects of marijuana on endocannabinoid system, which plays an important role in building brain pathways in fetus. Maggie Frank, a mom who is also a national educator, notes that the concerns with phytocannabinoid/CBD supplementation and pregnancy are due to the unknown. She says “we currently don’t have long-term research as to what happens years down the road as a result of utilizing hemp extracts in utero.”
Frank herself has used CBD successfully to treat hyperemesis gravidarum, a condition which brings along chronic severe morning sickness. She decided to use CBD although her doctor did not have a firm opinion on it but she believed it did not seem like it would be worse than the pharmaceutical’s risks. She started with 3mg of CBD oil and felt better the very first day. “It was like somebody flipped off the switch that was making me sick at all times,” she explains. She also reported feeling a considerable reduction in stress and anxiety level, experiencing better mood and sleep, less aches and pains plus more patience. Based on her own experience with CBD oil, Frank recommends using CBD during pregnancy but with caution. Purchasing a product that is third-party lab tested is crucial since it ensures you that there are zero traces of THC in the product. Dr. Talitha L. Burney, the medical doctor for the Comprehensive Family Care Center admits that although she has recognized all the benefits of CBD, even in pregnant women, the lack of government regulation is a key factor not to recommend its use.
How to Be Sure that CBD Oil Is Safe During Pregnancy?
Dr. Stuart Titus, a researcher and president of Medical Marijuana, believes that the safety of CBD can only be proven by studying the endocannabinoid system and its reaction to external cannabidiols. Dr. Titus explains that most people are cannabidiol deficient which can lead to chronic fatigue, dementia and even fibromyalgia. So, it is reasonable to believe that a cannabidiol-rich diet can be beneficial for both mother and fetus.
But there are studies which indicate that psychoactive nature of THC can interfere with the endocannabinoid system and can result in brain defects in unborn children. Although CBD is totally different from THC, they both work with the CB1 and CB2 receptors. These receptors are activated by natural cannabinoids in the body but they also show reactions to external cannabinoids such as THC and CBD. The main difference between these two, is that THC binds with these receptors but CBD only stimulates the natural cannabinoids in the body and consequently they activate the receptors. CBD does not bind with the receptors; therefore, it does not cause psychoactive effects.
Since the endocannabinoid system plays a crucial role in the creation of neurons and building brain pathways in the fetus brain, the effect of external cannabinoids on fetus should be observed carefully. Decades of research have revealed no association between cannabis use during pregnancy and premature birth, miscarriage or major physical abnormalities.
What Does the Research Say about CBD and Pregnancy?
Although the use of CBD during pregnancy has been risen significantly in the last few years, more research is still needed on this subject to prove that CBD is completely safe for pregnant women. Many doctors are aware of the benefits of CBD, but they hesitate in prescribing it to pregnant women. We probably have to wait for medical cannabis to become more mainstream on a global scale before we come to a real and firm conclusion that determines whether there are any side effects in using CBD during pregnancy.
Let’s take a look at what scientists have already found about the safety of CBD during pregnancy. In 2016, Dr Shayna Conna studied several cases in order to identify whether cannabis exposure has any result in postnatal development complications in babies. Surprisingly, the result indicated that cannabis, if used in isolation, does not have any negative birth complications or development issues.
In 1980s, two studies conducted by Dr. Melanie Dreher suggested that there is no visible significant difference between children who had been exposed to cannabis while in the womb, tested at the age of 3 days and later on at the age of 5 years.
In 2010, the National Center on Birth Defects and Developmental Disabilities conducted a research aimed at perinatal outcomes of using illicit drugs such as marijuana and other CBD products. During this research mothers who gave birth to healthy children between 1997 and 2004, were analyzed. The results showed that the prevalence rate of marijuana use during pregnancy was 3.6%. A majority of women who used CBD hemp oil during pregnancy were young and the drugs they had used did not influence the health of their newborns. CBD did not lead to lower birth weight or preterm delivery.
How to Use CBD During Pregnancy?
If you have come to the decision of using CBD oil to overcome the unpleasant health conditions related to pregnancy and have consulted with your doctor about it, here are some tips to help you get the best out of your CBD experience during pregnancy. Just remember that you should not do anything you feel uncomfortable with during pregnancy, so if you still have any hesitation don not act on word of mouth.
Smoking or using vaporizers are not recommended as it can have traces of THC of other harmful substances that might be harmful for you baby.
The safest way to consume CBD during pregnancy is a 100% CBD oil, that comes with a dropper or in the form of paste, capsules and lotions. If you are suffering from morning sickness, a few drops of CBD oil in the morning may help you a lot. If you have sore muscles you can easily apply CBD creams or oils topically. Just make sure you trust the supplier before purchasing any CBD product and check every ingredient the product contains. You should look for products made from organic hemp that does not contain any THC.
Although your doctor may not prescribe CBD oil for you, if you think it can be of any help controlling your unpleasant pregnancy symptoms, you should consult with your doctor to see whether its benefits outweigh the potential risks compared to other chemical substances and their associated negative side effects.
Luka Dončić Joins Team BioSteel as Global Chief Hydration Officer
BioSteel today announced a historic long-term global partnership between the sports hydration company and all-star basketball player, Luka Dončić. Dončić has been appointed the title of Global Chief Hydration Officer. The partnership with BioSteel makes Dončić the latest addition to the brand’s impressive athlete roster including Patrick Mahomes. ‘I’m excited to work with BioSteel as Global […]
BioSteel today announced a historic long-term global partnership between the sports hydration company and all-star basketball player, Luka Dončić. Dončić has been appointed the title of Global Chief Hydration Officer. The partnership with BioSteel makes Dončić the latest addition to the brand’s impressive athlete roster including Patrick Mahomes.
‘I’m excited to work with BioSteel as Global Chief Hydration Officer because I am passionate about the importance of healthy hydration on and off the court,’ says Dončić. ‘This partnership is a great opportunity for me to teach today’s youth about the importance of clean, healthy hydration using BioSteel’s sports drinks.’
‘It’s important to us that our partnerships are authentic as we continue to grow our brand,’ says Michael Cammalleri, Co-Founder and Co-CEO. ‘As the Official Sports Drink of the Dallas Mavericks, Luka has been hydrating with BioSteel’s zero sugar sports drink for the entire season. We’re thrilled to announce a new partnership with Luka, who believes in our product, to amplify our story and accelerate our growth.’
Dončić joins a growing list of top tier athletes and ambassadors, which reflect the company’s roots of working with those who were consumers of the brand prior to being formally endorsed by BioSteel. As a member of Team BioSteel, Dončić will extend the brand’s footprint by reaching new health-conscious consumers and aspiring athletes.
Off the court, Dončić is passionate about his philanthropic endeavors, having recently donated to the Dallas Mayor’s Fund for Dallas winter storm relief. He is an avid gamer, is a fan of anime and can speak four languages fluently.
BioSteel is expanding in the U.S. market at a rapid pace, securing the country’s top grocery, mass, gas and convenience retailers, with direct distribution partners across the country to support this growth.
BioSteel’s environmentally-friendly sports drink with zero sugar can be purchased at BioSteel.com.
BioSteel is a North American operated sports hydration company that was built on the mandate of providing the safest, healthiest, and most effective line of nutritional products available. BioSteel’s line includes a range of nutritional products including sports drinks, proteins, and everyday essentials. BioSteel products are currently readily available across North America, and globally with select retail partners or direct to consumers online, through www.biosteel.com.
SOURCE BioSteel Sports Nutrition Inc.
For further information: Lindsey Soper, Communications Manager, BioSteel Sports Nutrition Inc., 647-537-9512, email@example.com
Canopy Growth Corp. published this content on 03 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 March 2021 14:38:50 UTC
(C) Copyright 2021 – Canopy Growth Corp.
Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.
Australis and 3 Rivers Biotech Enter into Tissue Culture Joint Venture
Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) today announced that the Company has entered into a binding terms sheet concerning a joint venture (JV) partnership with 3 Rivers Biotech Inc. (“3 Rivers”), a leading agricultural technology company specialised in commercial scale micropropagation, or plant tissue culture (PTC), for cannabis, hemp and traditional crops. The JV […]
Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) today announced that the Company has entered into a binding terms sheet concerning a joint venture (JV) partnership with 3 Rivers Biotech Inc. (“3 Rivers”), a leading agricultural technology company specialised in commercial scale micropropagation, or plant tissue culture (PTC), for cannabis, hemp and traditional crops.
Under the terms of the agreement, AUSA and 3 Rivers will own 15% and 85% of the JV, respectively. The intent of the JV is to jointly market the 3 Rivers’ offerings to growers. Through the JV, 3 Rivers will provide access to its IP and innovative services, products and solutions to AUSA sourced clients. These innovations include all current 3 Rivers offerings as well as access to future products such as PTC-based auto-flowering genetics, which provides a clonal hemp or cannabis plant that will flower independent of day length. This is a potential game changer for outdoor growers. AUSA will contribute sales and marketing capabilities and, through its deep industry network, the ability to generate new opportunities.
With over 1,000 cannabis companies, close to 600,000 acres planted with hemp in North America and Europe alone (representing approximately 1.1 billion plants) 1 , as well as 1.3 million acres 2 (~56.6 billion square feet) of global greenhouse vegetable area, the opportunity for 3 Rivers is very substantial (these numbers leave out greenhouse production of fruit). Through its innovative offerings and in particular its nearly peerless capabilities in cannabis and hemp, the company is exceptionally well positioned to deliver significant growth. The joint venture with AUSA will generate mutual benefits through increased access to marketing channels addressing the various markets both AUSA and 3 Rivers operate in.
Advantages of PTC
PTC entails growing a plant from a small number of cells, rather than from seeds or clones, under strictly controlled sterile conditions in a nutrient medium. PTC has numerous benefits with a significant positive impact on growers’ economic returns:
Increased facility ROI through true Generation Zero plantlets: PTC delivers disease-free starting material, increasing vigor (faster and healthier growth), and improved metabolite (cannabinoid or terpene) expression (greater product quality), increasing the economic return of a facility
Increased facility efficiencies: when adopting PTC, a cultivator no longer requires a mother room, thereby freeing up licensed space for flowering of commercially valuable crop, increasing a facility’s yield
Reduced risk of crop failure due to pathogen infestation
100% feminized stock avoids risk of rogue male plants, which can destroy an entire harvest
100% traceability of inputs, genetics, and biomass reduces compliance risks
Reduced chance of failing strict pesticide testing with clean, laboratory-produced plants
Ability to remove pathogens from existing cultivars: producing ‘clean’ plantlets, enhancing yield and quality of a new crop
Preservation of Rare or Endangered Species
Accelerated Propagation Once a Plant is in Tissue Culture
Improved Harvest Timing: reducing labor requirement s
The 3 Rivers Offering
3 Rivers Biotech is a plant biotechnology company specializing in commercial scale plant tissue culture for cannabis, hemp and traditional crops to provide premium pathogen-free, pesticide-free, vigorous plants to cultivators and late-stage nurseries across the United States and Internationally. The 3 Rivers products and services include:
Supply of micropropagation derived genetics, disease free Generation Zero plantlets for cannabis, hemp and other traditional crops (fruits, flowers, ornamentals, vegetables, etc.)
Ongoing PTC facility management and medium supply services
Clean-up of existing genetics: delivering a new generation of disease-free plantlets to growers
Storage of rare and valuable cultivars: genetics are the core property based on which growers generate revenues and establish brands. Genetics are therefore exceptionally valuable and safeguarding these is of great importance. PTC enables the indefinite preservation of these genetics.
Genetic fingerprinting: ensuring traceability and IP protection
Pathogen testing: screening for all predatory viruses, fungi, and oomycetes
3 Rivers has developed a production ready, prefabricated PTC lab, capable of producing up to 500,000 plantlets per year, the so-called InstaLab. These InstaLabs, which can be shipped anywhere in the world, greatly accelerate a company’s ability to implement PTC at commercial scale
3 Rivers also designs and develops PTC production as part of a retrofit of existing facilities, or integrated into the design of new facilities
Further innovations around Integrated Pest Management and the delivery of PTC-stable autoflowering varieties, on which the company has a provisional patent, are under development.
Dr. Duke Fu , Interim CEO of AUSA, stated, “We believe this new partnership will set the standard for science-based micropropagation, and be accretive to AUSA’s results. Being able to offer the propagation of cannabis through tissue culture at commercially viable scale is something that many companies and scientists have attempted, but that very few, if any, have managed to accomplish. This makes the 3 Rivers capabilities unique. The JV provides AUSA with access to an expanded portfolio of extremely valuable IP. We also believe this will strengthen our ability to execute on our capital-light strategy. For instance, being able to offer cultivation partners with PTC reduces the need for our cultivars to take up space in their facilities’ mother rooms, increasing the yield of any given facility. This JV further cements AUSA’s position as an authentic differentiator by offering a unique value add service that is exceptionally difficult to replicate.”
Robert Allen , CEO of 3 Rivers, added: “This partnership is transformative to 3 Rivers. By teaming up with AUSA, we believe we will be able to access new sales and marketing channels and rapidly expand our global footprint for PTC of cannabis, hemp and traditional crops. The JV accelerates our ability to bring our commercially focused innovations to market by gaining access to a deep industry network of industry leaders and operators, and help establish 3 Rivers as the leading company in this exciting and economically rewarding field.”
About 3 Rivers
3 Rivers is operational in Canada and Washington State , and is expanding into California and other jurisdictions. Its Washington cannabis operations, serving the local market, are at capacity and the company is in the process of expanding its in-state capacity. Its California operations anticipate internal, partner driven demand to grow to approximately 4-5 million plantlets in the coming years, with further growth coming through external sales.
Through its partnership with JRT Nurseries and its large-scale Mount Vernon tissue culture facility, 3 Rivers has the ability to scale and ship plants globally. This facility is one of the largest and most reputable plant tissue culture nurseries in North America , capable of producing over 12+ million plants annually. TheMount Vernon facility will be leveraged to service global markets for micro-propagated traditional crops, such as soft fruits and vegetables.
3 Rivers eliminates the risks and variables of commercial cultivation by providing its customers with stable genetics and vigorous, disease-free clones. The deeply experienced 3 Rivers team, with over 50 million plants supplied and counting, has been focused on perfecting plant propagation for decades. The unique combination of commercial scale PTC for cannabis, science-based R&D on applications with a rapid time to market and broad service offering have resulted in 3 Rivers rapidly expanding into becoming a world leader in its field.
AUSA is implementing a growth strategy towards establishing a highly competitive and profitable MSO in the U.S. and global cannabis markets. AUSA’s business and assets include investments in Cocoon, Body and Mind Inc., Quality Green, Folium Biosciences, and land assets in Washington and Michigan . AUSA is currently working towards the closing of a transaction whereby it will acquire 51% of ALPS, the world’s premier design, construction management, commissioning and post commissioning consultancy for horticultural crops, such as cannabis, fruits, vegetables, mushrooms and algae. If completed, the Company will also hold an option for the acquisition of the remaining 49% of ALPS. AUSA is also working towards completing the acquisition of Green Therapeutics LLC, an award-winning MSO with operations in Nevada , Missouri and Oklahoma . Through GT and ALPS, the Company believes it will be able to secure low-cost access to cannabis biomass to fuel the scale up of its award-winning brands across the U.S. and global cannabis markets.
The Company’s common shares trade on the CSE under the symbol “AUSA” and on the OTCQB under the symbol “AUSAF”.
For further information about AUSA, please contact:
This press release contains “forward-looking information” within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein is forward-looking information. Generally, forward-looking information may be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. In particular, this press release contains forward-looking information in relation to: the the joint venture between AUSA and 3 Rivers closing and the ability to operate and execute; the timing and ability to close the proposed transactions with GT and ALPS; the anticipated development of the GT and ALPS businesses; the ability of the Company to execute on its strategy to establish a low capex model MSO; the impact of the changes to U.S. federal and state developments with respect to the cannabis industry and the opportunities this may present for the Company. This forward-looking information reflects the Company’s current beliefs and is based on information currently available to the Company and on assumptions the Company believes are reasonable. These assumptions include, but are not limited to: the ability of the Company to successfully satisfy the conditions to closing the ALPS and GT transactions; the ability of management of ALPS, GT and the Company to successfully execute on their respective business plans; legal changes relating to the cannabis industry proceeding as anticipated; and the Company’s continued response and ability to navigate the COVID-19 pandemic being consistent with, or better than, its ability and response to date.
Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; the actual results of the Company’s future operations; competition; changes in legislation affecting the Company; the timing and availability of external financing on acceptable terms; lack of qualified, skilled labour or loss of key individuals; risks related to the COVID-19 pandemic.
A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company’s disclosure documents on the SEDAR website at www.sedar.com . Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking information. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of the Company as of the date of this press release and, accordingly, are subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.
Constellation Brands Will Play A Huge Roll In The Success Of Canopy Growth’s U.S. CBD Beverage Rollout
The cannabis sector received a jolt of good news when Canopy Growth Corporation (WEED.TO) (CGC) announced a multi-faceted strategy to capitalize on the US cannabidiol (CBD) beverage market. Over the next year, we expect Canopy Growth to benefit from its strategic partnership with Constellation Brands (STZ), a multi-national beverage conglomerate that owns Corona. After Constellation […]
The cannabis sector received a jolt of good news when Canopy Growth Corporation (WEED.TO) (CGC) announced a multi-faceted strategy to capitalize on the US cannabidiol (CBD) beverage market.
Over the next year, we expect Canopy Growth to benefit from its strategic partnership with Constellation Brands (STZ), a multi-national beverage conglomerate that owns Corona. After Constellation announced its initial investment in Canopy Growth, we became very bullish on the long-term growth prospects of the Canadian cannabis company and are favorable on how the story has advanced since then.
Last night, Canopy Growth was featured on Jim Cramer’s Mad Money segment on CNBC. On the program, Canopy Growth CEO David Klein explained how it tests products in Canada before bringing them to the US market and has benefited from a test-and-learn process and expects Constellation to play a key role in how the product is distributed in the US.
This is not Canopy Growth’s first foray in the beverage market and in 2019, it acquired a majority stake of Biosteel, a sports nutrition products maker. CEO Klein expects Constellation to play an important role in how Biosteel branded products comes to market. We are favorable on the expertise that Constellation adds to the Canopy Growth team and expect the relationship to be a long-term leader in the global cannabis industry.
One of the reasons we are excited about the Quatreau CBD beverage line is based on its performance in Canada. Last year, Quatreau was the top-selling CBD beverage and benefited from a large spike in demand for cannabis-based products during the COVID pandemic.
The Quatreau beverage line that is sold in US will include 20 milligrams of hemp-based CBD that was grown in the US. We are favorable on the route that Canopy Growth is taking with sourcing premium hemp-based CBD and will be closely following this aspect of the story.
Although Canopy did not say when it plans to carry the product in US stores, we expect the brand to play an important role in its strategy to have a first mover advantage in the emerging US cannabis market and we will monitor how the leadership team from Canopy Growth and Constellation are able to execute on this.
During the last year, we have seen as pike in the number of Canadian cannabis prpdcuers that are focused on both the cannabis beverage and the US market. For instance, Aphria (APHA.TO) (APHA) and Tilray (TLRY) announced plans for a mega merger in late 2020. The development comes after Aphria acquired Sweetwater Brewing Company for approx. $300 million.
The combination of Aphria, Tilray and Sweetwater, creates a recipe to compete with Canopy Growth and this is an operator that our readers need to be aware of. We also expect Canopy Growth to face competition from HEXO Corp. (HEXO.TO) (HEXO) which is executing on the cannabis beverage vertical via a strategic partnership with Molson Coors Brewing (TAP).
If you are interested in learning about the companies that are positioned to capitalize on the cannabis beverage market, please send an email to firstname.lastname@example.org with the subject “Cannabis Beverage Leaders” to be added to our distribution list.
Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.